In a retrospective cohort study of 28,113 patients with ASCVD, an LLM analyzed clinical notes to detect treat-to-target lipid management and reasons lipid-lowering therapy (LLT) was not intensified. Among 13,394 patients with above-goal LDL-C in the inference set, treat-to-target language appeared in just 28.1% of notes, while LLT was not escalated in 88.7%—with adverse effects, patient preference, lifestyle preference, repeat labs, and near-goal LDL-C most often cited; the study was conducted in a large Northern California health system from 2019 to 2025.

Why It Matters To Your Practice

• Secondary prevention guidelines recommend tighter LDL-C control in ASCVD, but this study suggests documentation of treat-to-target care is uncommon and nonescalation is the norm when LDL-C remains at or above 70 mg/dL.

• The LLM performed at near-human reliability, with micro-weighted F1 scores from 0.80 to 0.98 and no statistically significant difference from interannotator reliability across measured outcomes.

• That means health systems may be able to audit real-world lipid management at scale without relying solely on manual chart review.

Clinical Implications

• If your patient with ASCVD has above-goal LDL-C, note-based reasons for not intensifying therapy may be more common than explicit LDL-C target documentation.

• Among notes without LLT escalation, 40.4% included at least one reason—most commonly patient-reported adverse effects (12.6%), LDL-C close to goal (6.9%), patient preference to avoid LLT (6.8%), preference for lifestyle changes (6.1%), and deferral for repeat labs (4.6%).

• These categories could help practices target interventions such as statin intolerance workflows, shared decision-making tools, follow-up lab protocols, and clinician prompts when LDL-C remains above guideline thresholds.

Insights

• Of 28,113 unique ASCVD patients, 13,810 (49.1%) had above-goal LDL-C at the most recent encounter.

• In the inference set, 3,756 of 13,354 relevant notes (28.1%) reflected a treat-to-target strategy, most often an LDL-C goal below 70 mg/dL (17.1% of notes).

• The findings suggest underuse of LLT is not explained by one factor alone; both clinical concerns and patient-centered reasons appear in the documentation.

The Bottom Line

• This study suggests an LLM can reliably extract lipid-management intent and barriers from routine notes in ASCVD care.

• For clinicians, the practical takeaway is that above-goal LDL-C often does not trigger LLT escalation, and the reasons are frequently documentable—and potentially actionable at the point of care.

Reference: AI-Identified Reasons for Nonescalation of Lipid-Lowering Therapy for Secondary Prevention.